SCHEMBL23330366

SCHEMBL23330366

CC(C)Cc1ccc2nccc(N)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.51
NCF1 P14598 1/20 0.44
PIK3CD O00329 1/20 0.41
ABL1 P00519 1/20 0.41
EGFR P00533 1/20 0.41
HCK P08631 1/20 0.41
SRC P12931 1/20 0.41
KDR P35968 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
MTOR P42345 1/20 0.41
PIK3CG P48736 1/20 0.41
EPHB4 P54760 1/20 0.41
PRKDC P78527 1/20 0.41
SOS2 Q07890 1/20 0.40
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
SMYD3 Q9H7B4 2/20 0.36
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23420994 0.87 NR4A2 (0.51) NR4A2NCF1PIK3CDABL1EGFR
SCHEMBL12044447 0.81 NR4A2 (0.56) NR4A2NCF1PIK3CDABL1EGFR
SCHEMBL31754329 0.78 PKM (0.53) NR4A2EGFRKDM4EHIF1A
SCHEMBL5018922 0.75 GABRA1 (0.44) GABRA1GABRB2KDM4EPOLBSMN1; SMN2
SCHEMBL25556184 0.75 NR4A2 (0.56) NR4A2NCF1PIK3CDABL1EGFR
SCHEMBL26664503 0.73 GABRA1 (0.47) NR4A2GABRA1GABRB2KDM4EPOLB
SCHEMBL25820094 0.72 SLC22A12 (0.42) GABRA1GABRB2
SCHEMBL8306581 0.72 NR4A2 (0.61) NR4A2NCF1PIK3CDABL1EGFR
SCHEMBL24150113 0.72 NR4A2 (0.61) NR4A2NCF1PIK3CDABL1EGFR
SCHEMBL831023 0.72 NOS3 (0.62) GABRA1GABRB2KDM4EPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210130473-A1 TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130473-A1 TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF TGFBR2, ASGR1, TGFBR1 NR4A2 904/4885NCF1 1836/4885PIK3CD 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.